Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Bergh, P. Jönsson, E. Lidbrink, M. Trudeau, W. Eiermann, D. Brattström, J. Lindemann, F. Wiklund, R. Henriksson (2012)
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 16
Stephen Fawell, R. White, Sue Hoare, Mark SYDENHAMt, Martin PAGEt, Malcolm Parker (1990)
Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.Proceedings of the National Academy of Sciences of the United States of America, 87 17
J. Robertson, A. Llombart-Cussac, J. Rolski, D. Feltl, J. Dewar, E. Macpherson, J. Lindemann, M. Ellis (2009)
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 27
J. Robertson, J. Lindemann, A. Llombart-Cussac, J. Rolski, D. Feltl, J. Dewar, L. Emerson, A. Dean, M. Ellis (2012)
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyBreast Cancer Research and Treatment, 136
G. Schiavon, S. Hrebien, I. Garcia-Murillas, R. Cutts, A. Pearson, N. Tarazona, K. Fenwick, I. Kozarewa, E. López-Knowles, Ricardo Ribas, A. Nerurkar, P. Osin, S. Chandarlapaty, L. Martin, M. Dowsett, I. Smith, N. Turner (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancerScience Translational Medicine, 7
A. Wakeling, J. Bowler (1987)
Steroidal pure antioestrogens.The Journal of endocrinology, 112 3
Shinji Ohno, Y. Rai, H. Iwata, N. Yamamoto, Masayuki Yoshida, H. Iwase, N. Masuda, Seigo Nakamura, H. Taniguchi, S. Kamigaki, S. Noguchi (2010)
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).Annals of oncology : official journal of the European Society for Medical Oncology, 21 12
Anthony Howell, J. Robertson, J. Albano, A. Aschermannová, L. Mauriac, Ulrich Kleeberg, I. Vergote, B. Erikstein, A. Webster, Charles Morris (2002)
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 16
A. Leo, G. Jerusalem, L. Petruželka, R. Torres, I. Bondarenko, R. Khasanov, D. Verhoeven, J. Pedrini, I. Smirnova, M. Lichinitser, K. Pendergrass, Sally Garnett, J. Lindemann, F. Sapunar, Miguel Martín (2010)
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 30
K. Pritchard, J. Rolski, Z. Pápai, L. Mauriac, F. Cardoso, José Chang, L. Panasci, C. Ianuli, Z. Kahán, K. Fukase, J. Lindemann, M. Macpherson, P. Neven (2010)
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)Breast Cancer Research and Treatment, 123
R. Jeselsohn, Gilles Buchwalter, C. Angelis, Myles Brown, R. Schiff (2015)
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancerNature Reviews Clinical Oncology, 12
J. Baselga, S. Im, H. Iwata, M. Clemons, Yoshinori Ito, A. Awada, S. Chia, Agnieszka Jagie, o-Gruszfeld, B. Pistilli, L. Tseng, S. Hurvitz, N. Masuda, J. Cortés, M. Laurentiis, C. Arteaga, Zefei Jiang, W. Jonat, S. Hachemi, S. Mouhaër, E. Tomaso, P. Urban, C. Massacesi, M. Campone (2015)
PIK3CA Status in Circulating Tumor DNA Predicts Efficacy of Buparlisib Plus Fulvestrant in Postmenopausal Women With Endocrine-resistant HR+/HER2- Advanced Breast Cancer: First Results From the Randomized, Phase III BELLE-2 Trial
R. Mehta, W. Barlow, K. Albain, T. Vandenberg, S. Dakhil, Nagendra Tirumali, D. Lew, D. Hayes, J. Gralow, R. Livingston, G. Hortobagyi (2012)
Combination anastrozole and fulvestrant in metastatic breast cancer.The New England journal of medicine, 367 5
Y. Chia, Cynthia Ma (2009)
Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECTBreast Diseases: A Year Book Quarterly, 20
R. Jeselsohn, R. Yelensky, Gilles Buchwalter, G. Frampton, F. Meric-Bernstam, A. González-Angulo, J. Ferrer-Lozano, J. Pérez-Fidalgo, M. Cristofanilli, H. Gómez, C. Arteaga, J. Giltnane, J. Balko, M. Cronin, M. Jarosz, James Sun, Matthew Hawryluk, D. Lipson, G. Otto, J. Ross, A. Dvir, L. Soussan-Gutman, I. Wolf, T. Rubinek, Lauren Gilmore, S. Schnitt, S. Come, L. Pusztai, P. Stephens, Myles Brown, V. Miller (2014)
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 20
C. Fribbens, B. O’Leary, L. Kilburn, S. Hrebien, I. Garcia-Murillas, M. Beaney, M. Cristofanilli, F. André, S. Loi, S. Loibl, John Jiang, C. Bartlett, M. Koehler, M. Dowsett, J. Bliss, S. Johnston, N. Turner (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 25
S. Movérare-Skrtic, A. Börjesson, H. Farman, K. Sjögren, S. Windahl, M. Lagerquist, A. Andersson, A. Stubelius, H. Carlsten, J. Gustafsson, C. Ohlsson (2014)
The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modifiedProceedings of the National Academy of Sciences, 111
I. Krop, I. Mayer, V. Ganju, M. Dickler, S. Johnston, S. Morales, D. Yardley, B. Melichar, A. Forero-Torres, S. Lee, R. Boer, K. Petráková, S. Vallentin, E. Perez, M. Piccart, M. Ellis, E. Winer, S. Gendreau, M. Derynck, M. Lackner, G. Levy, J. Qiu, Jing He, P. Schmid (2016)
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.The Lancet. Oncology, 17 6
I. Kuter, J. Gee, R. Hegg, C. Singer, R. Badwe, E. Lowe, U. Emeribe, E. Anderson, F. Sapunar, P. Finlay, R. Nicholson, J. Bines, N. Harbeck (2012)
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II studyBreast Cancer Research and Treatment, 133
(Baselga J, Im S-A, Iwata H, et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium. 2015;Abstract S6-01.)
Baselga J, Im S-A, Iwata H, et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium. 2015;Abstract S6-01.Baselga J, Im S-A, Iwata H, et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium. 2015;Abstract S6-01., Baselga J, Im S-A, Iwata H, et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): first results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium. 2015;Abstract S6-01.
K. O'reilly, F. Rojo, Q. She, D. Solit, G. Mills, Debra Smith, H. Lane, F. Hofmann, D. Hicklin, D. Ludwig, J. Baselga, N. Rosen (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.Cancer research, 66 3
J. Robertson, I. Bondarenko, E. Trishkina, M. Dvorkin, L. Panasci, A. Manikhas, Y. Shparyk, S. Cardona-Huerta, K. Cheung, M. Philco-Salas, M. Ruiz-Borrego, Z. Shao, S. Noguchi, J. Rowbottom, M. Stuart, L. Grinsted, M. Fazal, M. Ellis (2016)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialThe Lancet, 388
A. Leo, G. Jerusalem, L. Petruželka, R. Torres, I. Bondarenko, R. Khasanov, D. Verhoeven, J. Pedrini, I. Smirnova, M. Lichinitser, K. Pendergrass, L. Malorni, Sally Garnett, Y. Rukazenkov, Miguel Martín (2013)
Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM TrialJNCI Journal of the National Cancer Institute, 106
D. Robinson, Yi-Mi Wu, Pankaj Vats, Fengyun Su, R. Lonigro, Xuhong Cao, Shanker Kalyana-Sundaram, Rui Wang, Yu Ning, L. Hodges, Amy Gursky, J. Siddiqui, S. Tomlins, S. Roychowdhury, K. Pienta, Scott Kim, J. Roberts, J. Rae, C. Poznak, D. Hayes, R. Chugh, L. Kunju, M. Talpaz, A. Schott, A. Chinnaiyan (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancerNature Genetics, 45
R. Finn, J. Crown, J. Ettl, Marcus Schmidt, I. Bondarenko, I. Láng, T. Pintér, K. Boér, Ravi Patel, S. Randolph, Sindy Kim, Xin Huang, P. Schnell, S. Nadanaciva, C. Bartlett, D. Slamon (2016)
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18Breast Cancer Research : BCR, 18
(Fasching PA, Jerusalem GHM, Pivot X, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol. 2016;34(Suppl):Abstract TPS624.)
Fasching PA, Jerusalem GHM, Pivot X, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol. 2016;34(Suppl):Abstract TPS624.Fasching PA, Jerusalem GHM, Pivot X, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol. 2016;34(Suppl):Abstract TPS624., Fasching PA, Jerusalem GHM, Pivot X, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3. J Clin Oncol. 2016;34(Suppl):Abstract TPS624.
(Di Leo A, Seok Lee K, Ciruelos E. BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. San Antonio Breast Cancer Symposium. 2016;Abstract S4-07.)
Di Leo A, Seok Lee K, Ciruelos E. BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. San Antonio Breast Cancer Symposium. 2016;Abstract S4-07.Di Leo A, Seok Lee K, Ciruelos E. BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. San Antonio Breast Cancer Symposium. 2016;Abstract S4-07., Di Leo A, Seok Lee K, Ciruelos E. BELLE-3: a phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. San Antonio Breast Cancer Symposium. 2016;Abstract S4-07.
C. Osborne, A. Wakeling, R. Nicholson (2004)
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of actionBritish Journal of Cancer, 90
A. Howell, J. Robertson, P. Abram, M. Lichinitser, R. Elledge, E. Bajetta, Toru Watanabe, C. Morris, A. Webster, I. Dimery, C. Osborne (2004)
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 9
Shi-Yong Sun, L. Rosenberg, Xuerong Wang, Zhongmei Zhou, P. Yue, H. Fu, F. Khuri (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.Cancer research, 65 16
J. Baselga, S. Im, H. Iwata, M. Clemons, Yoshinori Ito, A. Awada, S. Chia, A. Jagiełło-Gruszfeld, B. Pistilli, L. Tseng, S. Hurvitz, N. Masuda, J. Cortes, M. Laurentiis, C. Arteaga, Zefei Jiang, W. Jonat, S. Hachemi, S. Mouhaër, E. Tomaso, P. Urban, C. Massacesi, M. Campone (2016)
Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:Cancer Research, 76
S. Howell, S. Johnston, A. Howell (2004)
The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.Best practice & research. Clinical endocrinology & metabolism, 18 1
M. Ellis, A. Llombart-Cussac, D. Feltl, J. Dewar, M. Jasiówka, N. Hewson, Y. Rukazenkov, J. Robertson (2015)
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST StudyJournal of Clinical Oncology, 33
J. Braybrooke (2013)
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial
(2008)
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECTJ Clin Oncol, 26
A. Leo, K. Lee, E. Ciruelos, P. Lønning, W. Janni, R. O'Regan, M. Reynier, D. Kalev, D. Egle, T. Csőszi, R. Bordonaro, T. Decker, V. Tjan-Heijnen, S. Blau, A. Schirone, D. Weber, M. El-Hashimy, Bharani Dharan, D. Sellami, T. Bachelot (2017)
Abstract S4-07: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatmentCancer Research, 77
J. Spoerke, S. Gendreau, K. Walter, J. Qiu, T. Wilson, H. Savage, J. Aimi, M. Derynck, Meng Chen, Iris Chan, L. Amler, G. Hampton, S. Johnston, I. Krop, P. Schmid, M. Lackner (2016)
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrantNature Communications, 7
B. Tine, R. Crowder, M. Ellis (2011)
ER and PI3K independently modulate endocrine resistance in ER-positive breast cancer.Cancer discovery, 1 4
M. Fan, E. Rickert, Lei Chen, S. Aftab, K. Nephew, R. Weatherman (2007)
Characterization of molecular and structural determinants of selective estrogen receptor downregulatorsBreast Cancer Research and Treatment, 103
C. Osborne, J. Pippen, S. Jones, Leroy Parker, M. Ellis, S. Come, Stan Gertler, J. May, Gary Burton, I. Dimery, A. Webster, C. Morris, R. Elledge, Aman Buzdar (2002)
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 16
M. Cristofanilli, N. Turner, I. Bondarenko, J. Ro, S. Im, N. Masuda, M. Colleoni, A. DeMichele, S. Loi, S. Verma, H. Iwata, N. Harbeck, Ke Zhang, K. Theall, Yuqiu Jiang, C. Bartlett, M. Koehler, D. Slamon (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.The Lancet. Oncology, 17 4
J. Robertson, C. Osborne, A. Howell, Stephen Jones, L. Mauriac, M. Ellis, U. Kleeberg, S. Come, I. Vergote, S. Gertler, A. Buzdar, A. Webster, C. Morris (2003)
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal womenCancer, 98
R Nicholson, J. Gee, D. Manning, A. Wakeling, M. Montano, B. Katzenellenbogen (1995)
Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancer aAnnals of the New York Academy of Sciences, 761
G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap, G. Sonke, S. Paluch-Shimon, M. Campone, K. Blackwell, F. André, E. Winer, W. Janni, S. Verma, P. Conte, C. Arteaga, D. Cameron, K. Petráková, L. Hart, C. Villanueva, A. Chan, E. Jakobsen, A. Nusch, O. Burdaeva, E. Grischke, E. Alba, E. Wist, N. Marschner, A. Favret, D. Yardley, T. Bachelot, L. Tseng, S. Blau, F. Xuan, F. Souami, Michelle Miller, C. Germa, S. Hirawat, J. O’Shaughnessy (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.The New England journal of medicine, 375 18
B. O’Leary, R. Finn, N. Turner (2016)
Treating cancer with selective CDK4/6 inhibitorsNature Reviews Clinical Oncology, 13
Fulvestrant is a selective estrogen receptor degrader that binds, blocks and degrades the estrogen receptor (ER), leading to complete inhibition of estrogen signaling through the ER. This review article further explains the mechanism of action of the drug and goes on to review the trials carried out to optimize its dosing. Multiple trials have been undertaken to compare fulvestrant with other endocrine treatments, and results have shown it to have similar efficacy to anastrozole, tamoxifen and exemestane at 250 mg every 28 days. However, when given at 500 mg every 28 days, with an extra loading dose on day 14, it has demonstrated an improved progression-free survival (PFS) compared to anastrozole. We look at how fulvestrant has been used in combination with CDK4/6 inhibitors such as palbociclib (PALOMA-3) and ribociclib (MONALEESA-3) and drugs targeting the PI3K/AKT/mTOR pathway such as pictilisib (FERGI) and buparlisib (BELLE-2 and BELLE-3). We then go on to describe a selection of the ongoing clinical trials looking at combination therapy involving fulvestrant. Finally, we review the effect of fulvestrant in patients who have developed resistance to aromatase inhibitors via ESR1 mutation, where it has been shown to offer a PFS benefit that is further improved by the addition of the CDK4/6 inhibitor palbociclib. Whilst fulvestrant is clearly an effective drug as monotherapy, we believe that its role in the treatment of ER-positive breast cancer may be best reserved for combination therapy, and whilst there are multiple trials currently in progress, it would appear that the combination with CDK4/6 inhibitors would offer the greatest promise in terms of balancing benefit with toxicity.
Oncology and Therapy – Springer Journals
Published: May 8, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.